Skip to main content
Home > BioCentury on BioBusiness > Tools & Tech

Chronological Index of BioCentury, The Bernstein Report on BioBusiness: Tools & Techniques

BioCentury, The Bernstein Report on BioBusiness Current Issue
  • Bridled enthusiasm

    When it comes to the politics of embryonic stem cell technology, it seems that every word must be vetted, analyzed and then reanalyzed. The latest …

    Published on 8/28/2006
  • Neurogenesis filter

    Technology Briefing Neurogenesis filter BrainCells Inc. was formed in 2003 based on the idea that neurogenesis, the growth of new nerve tissue from a multipotent neural stem cell population, can be manipulated using…

    Published on 8/21/2006
  • TWEAKing RA

    Technology Briefing TWEAKing RA In addition to TNF inhibitors, the ranks of biologics used to treat rheumatoid arthritis now include drugs that target T and B cells. The treatments use different mechanisms, but the …

    Published on 8/21/2006
  • Mapping AMD

    Technology Briefing: Sitting at the AMD nexus Mapping AMD Selected compounds in or about to enter the clinic for age-related macular degeneration Company Product Description Status Genaera Evizon squalamine …

    Published on 8/14/2006
  • Breast cancer tests: Same difference

    Researchers reported in the New England Journal of Medicine that even though different diagnostic developers have created tests for …

    Published on 8/14/2006
  • Microfluidics in 3-D

    Technology Briefing Microfluidics in 3-D Researchers published in the Proceedings of the National Academy of Sciences the development of a technique to produce microfluidic devices composed of polydimethylsiloxane (…

    Published on 8/14/2006
  • More pep against infection

    Technology Briefing More pep against infection Ceragenins are cationic steroid antibiotics (CSAs) that are small molecule mimics of antimicrobial peptides. Active against a broad range of Gram-positive and -negative…

    Published on 8/14/2006
  • Sitting at the AMD nexus

    Technology Briefing Sitting at the AMD nexus Mapping AMD Potentia Pharmaceuticals Inc. last week licensed exclusive worldwide rights to the Compstatin class of C3 inhibitors from the University of Pennsylvania. The…

    Published on 8/14/2006
  • Concentrating on HTS

    Technology Briefing Concentrating on HTS When James Inglese and Douglas Auld were getting their screening lab set up at NIH, they encountered more red tape than expected. As a result, the researchers found …

    Published on 8/7/2006
  • Soluble stability

    Technology Briefing Soluble stability The ability to identify stable and soluble human antibody fragments, coupled with the potential upside from an unpartnered lead program, has enabled ESBATech AG to attract CHF50…

    Published on 8/7/2006
  • Mapping the S1P system

    Researchers published a study in Nature Chemical Biology this month shedding more light on the importance of the sphingosine 1-phosphate (S1P) …

    Published on 7/24/2006
  • Alzheimer’s vaccine, round 2

    Scientists from the Tokyo Metropolitan Institute for Neuroscience and Novartis AG have published a nonviral amyloid beta DNA vaccine …

    Published on 6/19/2006
  • Sequencing stimulant

    Leapfrogging is the name of the game in the supplier space, even if new tools cannibalize one's own products. Thus Applied Biosystems …

    Published on 6/12/2006
  • PI3K vs. PLC gamma

    Technology Briefing: Angiogenesis switch PI3K vs. PLC gamma Phosphatidylinositol (PI) is an important lipid, both as a key cell membrane constituent and, more importantly for drug developers, as a participant in …

    Published on 6/5/2006
  • Angiogenesis switch

    PI3K vs. PLC gamma Blocking angiogenesis is a popular therapeutic strategy, but the intracellular switch that governs whether blood …

    Published on 6/5/2006
  • Envisioning plasticity

    Technology Briefing Envisioning plasticity Italian researchers have shown that surgery plus injections of chondroitinase ABC (chABC), an enzyme that degrades chondroitin and some closely related proteins, helps …

    Published on 5/22/2006
  • Finding the invisible

    Technology Briefing Finding the invisible Merck & Co. Inc. scientists published in Nature the discovery of platensimycin, a new antibiotic class with broad Gram-positive antibacterial activity that works by …

    Published on 5/22/2006
  • Fingering IL-23, again

    Technology Briefing Fingering IL-23, again The similarities between chronic and tumor-associated inflammation, such as increased angiogenesis and vasculature density, have been well documented. Researchers from …

    Published on 5/22/2006
  • Discovering innate memory

    Technology Briefing Discovering innate memory Harvard researchers have discovered that natural killer cells have memory and can mount antigen-specific responses, similar to T cells and B cells. The finding indicates…

    Published on 5/15/2006
  • Habeas corpus

    Technology Briefing Habeas corpus With the close of a $60 million financing tranche earlier this year, CovX Pharmaceuticals Inc. has quietly raised a total of $105 million from Tavistock Life Sciences since it was …

    Published on 5/15/2006
  • Turning T cells off

    Technology Briefing Turning T cells off Argos Therapeutics Inc. says CD83, the therapeutic protein it recently in-licensed from Beckman Coulter Inc., may serve as a switch that turns off autoimmunity. The company is…

    Published on 5/15/2006
  • Detective work

    Although the heat from clinical and product blowups eventually subsides, researchers continue to try to elucidate the causes of the setbacks. …

    Published on 5/1/2006
  • LNA chasing miRNAs

    Technology Briefing LNA chasing miRNAs As more and more microRNAs are discovered, researchers want to rapidly validate the regulatory molecules' relevance as therapeutic targets. Santaris Pharma A/S, which believes …

    Published on 5/1/2006
  • Locked and loaded conjugates

    Technology Briefing Locked and loaded conjugates An article to be published in this week's Proceedings of the National Academy of Sciences describes a dock and lock (DNL) protein engineering method from Immunomedics…

    Published on 5/1/2006
  • One point scores twice

    Technology Briefing One point scores twice Nautilus Biotech S.A. says that single point mutations it introduced into interferon alpha and human growth hormone not only have conferred better potency and duration of …

    Published on 5/1/2006

< Previous   1  2  3  4  5  6  7  8  9  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

BioCentury on BioBusiness

BioCentury, The Bernstein Report on BioBusiness is globally recognized for industry analysis, interpretation and commentary on:

  • Corporate Strategy
  • Product Discovery and Development
  • Finance
  • Emerging Companies
  • Regulatory Policy
  • Public Policy